Pennsylvania State University

Pennsylvania State University, operating as Penn State Milton S. Hershey Medical Center, is a state-controlled 1862 Land Grant institution that serves as a prime recipient of federal research and development grants, primarily in biomedical sciences. The entity operates as a child organization within the larger Pennsylvania State University system and competes predominantly in full-and-open federal grant competitions across the National Institutes of Health and allied federal research agencies—with no set-aside designations.

Penn State Hershey Medical Center's federal footprint is nearly entirely grant-based, concentrated in basic and translational biomedical research. Over the past five years, the institution has been a prime recipient of project grants from NIAID (56 awards, $170.6 million combined potential value, including a single-award IDC ceiling of $146.3 million through July 2031 for pre-clinical models of infectious diseases), the National Cancer Institute (79 awards), the National Heart, Lung, and Blood Institute (73 awards), and the National Institute of Neurological Disorders and Stroke (47 awards). Across the top five NIH component customers alone, the institution holds 503 award records. Work spans fundamental neuroscience research (cerebellothalamocortical communication, polyomavirus innate immunity, dopamine signaling in opioid relapse), virology and infectious disease (HIV genome packaging mechanisms, papillomavirus models, Hepatitis B capsid structure), behavioral health and addiction science (sleep and circadian dysfunction in autism and ADHD, alcohol-nicotine co-use neuroimmunology, psilocybin for PTSD-related pain), oncology (neuroblastoma extracellular-vesicle targeting, lung adenocarcinoma immunotherapy, pediatric leukemia disparities in Hispanic populations), and precision medicine across cardiovascular, metabolic, and rheumatologic domains. Representative recent awards include a $708.697 million grant from NIDDK on mesenchymal cell activation in ulcerative colitis (2026–2029), a $704.700 million grant from NIMH on transdiagnostic sleep and circadian intervention for autistic youth (2026–2029), and a $1.948 million grant from NIAMS on post-transcriptional gene regulation in bone regeneration (2025–2028).

The institution reports 86% of recent awards as prime (879 awards) and 14% as sub-awards (144 awards), indicating a predominantly prime-recipient posture. Federal agency concentration is high: the top five customer agencies (all NIH institutes and centers) account for 49% of the award count and an even larger share of combined potential value. Department of Health and Human Services National Institutes of Health dominates across all ranked customer lists. The Defense Health Agency, Department of the Army Medical Command, and Department of Defense account for a small but visible secondary customer base in military medical research and health services support.

Activity has remained robust across the past five years (71 awards in 2023, 81 in 2024, 64 in 2025), with 122 awards (combined potential value $1.2 million) reaching ultimate completion within the next twenty-four months, presenting both recompete opportunities for competitors and pipeline-renewal pressure for the institution. The Service Contract Inventory dataset shows limited federal services-contract activity captured above the $150,000 reporting threshold—6 records across FY2022–FY2024, all in subcontractor roles, with FTE trajectories showing 0.6 FTEs in FY2022 escalating to 4.7 FTEs in FY2024. This sparse SCI footprint reflects the institution's orientation toward research grants rather than time-and-materials or labor-hour service contracts.

Penn State Hershey Medical Center operates as a major research institution but does not appear in the federal contract (as opposed to grant) marketplace in any significant volume. The entity is a child of The Pennsylvania State University, a Tax Exempt Not-for-Profit entity headquartered in State College, Pennsylvania, and carries the Land Grant college designation. The institution's research mission and NIH-dominated funding profile position it as a competitor for basic biomedical research dollars and a collaborative partner for multi-site clinical and translational studies rather than a federal contractor.